About

About
The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Pipeline
DS Biopharma have three novel assets in various stages of clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.

Investors

Investors
To date, DS Biopharma have been funded privately.

Publications and Media Coverage

January 19, 2021

DS BIOPHARMA ABSTRACTS ACCEPTED AT THE ATOPIC DERMATITIS CENTRE OF REFERENCE AND EXCELLENCE (ADCARE) 2021 CONFERENCE

DS Biopharma (DS) has successfully submitted two abstracts to the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference. A link to the abstract “Steroid-sparing […]
November 19, 2019

Pipeline full with agents in various phases of development | Dermatology Times

The following article appeared in Dermatology Times on 19th November 2019: https://www.dermatologytimes.com/atopic-dermatitis/pipeline-full-agents-various-phases-development As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data […]

Latest Press Releases

March 6, 2019

Clinical Study Shows Topical DS107 Prevents Disease Exacerbation in Atopic Dermatitis Patients

Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]

Join our mailing list

Connect with us